Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LOXO-338 + Pirtobrutinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LOXO-338 | LOXO338|LOXO 338 | BCL2 inhibitor 27 | LOXO-338 inhibits BCL2, potentially leading to inhibition of tumor cell proliferation and tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1258). | |
Pirtobrutinib | Jaypirca | LOXO-305|LOXO 305|LOXO305|RXC005|REDX08608 | BTK inhibitor 37 | Jaypirca (pirtobrutinib) selectively inhibits the activation of BTK, which may result in decreased tumor growth (PMID: 32170458, PMID: 33676628). Jaypirca (pirtobrutinib) is FDA approved for use in patients with relapsed or refractory mantle cell lymphoma who had received at least two lines of systemic therapy, and in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05024045 | Phase I | LOXO-338 + Pirtobrutinib LOXO-338 | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | Active, not recruiting | USA | POL | ITA | FRA | 0 |